Close

News

Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of Pharmaceutical Strategies Group’s (PSG) 340B Link business, pursuant to the terms...

Siegfried to Acquire Two Pharmaceutical Manufacturing Sites from Novartis in Spain

Siegfried has signed binding agreements with Novartis regarding the acquisition of two pharmaceutical manufacturing sites in Spain. With this acquisition, Siegfried will significantly enhance its global production network in terms of capacity and technological capabilities and will achieve the...

BMS Announces Update on CheckMate -915 Evaluating Opdivo Plus Yervoy Versus Opdivo in Resected High-Risk Melanoma Patients

Bristol Myers Squibb announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients who have had a complete surgical removal of stage IIIb/c/d or stage...

EMA starts first rolling review of a COVID-19 vaccine in the EU

EMA’s human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by the company AstraZeneca in collaboration with the University of Oxford. The start of the rolling review means that the committee...

AstraZeneca: COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). A standard review process triggered a voluntary pause to vaccination across all global trials on...

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This...

Dr. Reddy’s Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA). The Sensipar brand and generic market had U.S. sales of approximately $312...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read